Bli medlem
Bli medlem

Du är här


Hansa Medical: Hansa Medical's rights issue oversubscribed

Hansa Medical's rights issue with preferential rights has been
subscribed at 137 percent of which 99 percent was subscribed through
preferential rights. The rights issue comprises 3.7 million shares at
SEK 10 per share, which brings SEK 37 million to the company before
issue expenses. The capital will be used for Phase II-studies with
the drug candidate IdeS during 2014 and 2015.

An extraordinary general meeting held on March 5, 2014, resolved to
carry through a rights issue of at the most 3 704 229 shares with
preferential rights at SEK 10 per share. The subscription period for
the offer was between March 25 and April 8.

In total 3 658 875 shares have been subscribed for with preferential
rights, which corresponds to 99 percent of the number of shares
issued. In addition, 1 417 323 shares were subscribed for without
preferential rights, corresponding to 38 percent of the number of
shares issued. Shares being subscribed for without preferential
rights will be assigned according to the principles described in the
prospectus published on March 19, 2014. No rights issue guarantee
will be applied due to the oversubscription of the rights issue.

The rights issue increases the number of Hansa Medical shares with 3
704 229 shares to a total amount of 25 929 603 shares. Following the
rights issue, the share capital amounts to 25 929 603.

Paid subscribed shares, subscribed with preferential rights, is traded
under short name HMED BTA 1 at NASDAQ OMX First North until the end
of April when they will be converted to shares. Paid subscribed
shares, subscribed without preferential rights, will be traded under
short name HMED BTA 2 starting at the end of next week.

For further information, please contact:
Hansa Medical AB
Emanuel Björne, CEO Hansa Medical AB (publ)
Mobile: 46 707 17 54 77

Hansa Medical pursues clinical development and commercialization of
innovative pharmaceuticals and diagnostic methods for the benefit of
patients with serious and rare inflammatory diseases. The portfolio
includes a marketed diagnostic product, a drug candidate in clinical
development, and a preclinical research project. Major shareholders
are Bo Håkansson via Farstorps Gård AB, and Nexttobe AB. Hansa
Medical is listed on NASDAQ OMX First North (HMED) and Remium Nordic
AB is the company's Certified Adviser. The information in this press
release is such information that Hansa Medical AB (publ) is obliged
to disclose under the Securities Market Act and/or the Financial
Instruments Trading Act. The information was made public on April 11,
2014 at 08:30 CET.


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.